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Abstract
Oropharyngeal candidiasis (OPC, thrush) is an opportunistic infection caused by the commensal 
fungus Candida albicans. IL-17 and IL-22 are cytokines produced by Type 17 lymphocytes. Both 
cytokines mediate antifungal immunity yet activate quite distinct downstream signaling pathways. 
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While much is now understood about how IL-17 promotes immunity in OPC, the activities of 
IL-22 are far less well delineated. We show that, despite having similar requirements for induction 
from Type 17 cells, IL-22 and IL-17 function non-redundantly during OPC. We find that the IL-22 
and IL-17 receptors are required in anatomically distinct locations within the oral mucosa; loss of 
IL-22RA1 or STAT3 in the oral basal epithelial layer (BEL) causes susceptibility to OPC, whereas 
IL-17RA is needed in the suprabasal epithelial layer (SEL). Transcriptional profiling of the tongue 
linked IL-22/STAT3 to oral epithelial cell proliferation and survival, but also, unexpectedly, to 
driving an IL-17-specific gene signature. We show that IL-22 mediates regenerative signals on the 
BEL that replenish the IL-17RA-expressing SEL, thereby restoring the ability of the oral 
epithelium to respond to IL-17 and thus to mediate antifungal events. Consequently, IL-22 
signaling in BEL ‘licenses’ IL-17 signaling in the oral mucosa, revealing spatially distinct yet 
cooperative activities of IL-22 and IL-17 in oral candidiasis.
One sentence summary
IL-22 signaling limits oral candidiasis via proliferation of basal epithelial cells and replenishment 
of an IL-17-responsive layer.
INTRODUCTION
Fungal infections are a serious threat to public health, but our understanding of immunity to 
fungi lags behind that of other microbes (1). Even today there are no licensed vaccines to 
any fungal microbes (2, 3). Oropharyngeal candidiasis (OPC, thrush) is an opportunistic 
infection of the oral mucosa caused by the commensal fungus Candida albicans. OPC occurs 
commonly in the settings of HIV/AIDS, head and neck cancer radiation treatment, 
immunosuppressive therapies, or the suboptimal immune responses in infants and the elderly 
(4, 5). OPC is also a characteristic infection of patients with gene mutations impairing the 
IL-17/Th17 pathway, such as STAT3, ACT1, IL17RA or IL17RC, among others (6–9). 
Consistently, whereas immunocompetent wild type (WT) mice are resistant to OPC, 
corticosteroid immunosuppression or loss-of-function mutations in the IL-17 receptor 
(Il17ra, Il17rc) or related genes (Act1, Il23, Il12b or Rorc) result in high susceptibility to 
OPC (10–14). However, peak oral fungal burdens in susceptible Il17ra−/− mice are still 
lower than in animals immunosuppressed with corticosteroids (12), indicating that signals in 
addition to IL-17 are needed for full protection in OPC.
Although IL-17 is the eponymous cytokine of Th17 cells and other ‘Type 17’ lymphocytes, 
IL-22 is also characteristic of these cells (15). Multiple studies indicate that IL-22, like 
IL-17, helps control oral candidiasis. For example, OPC occurs in patients with autoimmune 
polyendocrine syndrome type 1 (APS-1), a congenital autoimmune syndrome caused by 
mutations in AIRE and characterized by circulating auto-antibodies that neutralize not only 
IL-17A and IL-17F but also IL-22 (16–19). Mice with IL-22 impairments (via gene 
deficiency or antibody neutralization) are susceptible to OPC (12, 20, 21), and reduced 
IL-22 expression is associated with human chronic mucocutaneous candidiasis (CMC) (8). 
Nonetheless, relatively little is known about the mechanisms of antifungal immunity 
mediated by IL-22 in this setting or in other oral diseases.
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The oral mucosa provides a vital physical barrier to limit pathogen invasion, yet mechanisms 
of oral mucosal immunity remain surprisingly under-studied, especially compared to other 
mucosal tissues such as the lung or gut. During OPC, oral epithelial cells (OECs) sense the 
transition of C. albicans from a benign yeast morphotype to a damaging, invasive hyphal 
state (22). This early recognition is mediated in part by EGFR family receptors and also 
involves sensing of oral tissue damage induced by a secreted fungal toxin, candidalysin (23–
27). This OEC immunosurveillance response triggers production of IL-17 from lymphocytes 
(both innate and adaptive) via IL-1-dependent signals (28–30). IL-17 then activates essential 
antifungal responses in OECs, including myeloid and lymphoid chemoattractants and 
antimicrobial peptides (AMPs), particularly β defensin-3 (BD3) (5, 12, 31–33).
The oral mucosa is a stratified non-keratinizing tissue composed of distinct epithelial layers 
(34, 35). A proliferative basal epithelial layer (BEL) undergoes a program of differentiation 
that gives rise to the post-mitotic suprabasal epithelial layer (SEL). This differentiation 
process maintains the tissue and restores barrier immunity after infection or injury (35–37). 
Each layer is characterized by expression of specific pairs of cytokeratin filaments. Like 
most stratified epithelia, BEL expresses keratins-5 and −14 (K14, K5). However, the SEL 
expresses K4 and K13, which have a more restricted expression pattern. IL-17R signaling 
activity is generally restricted to non-hematopoietic cells (38, 39), and we previously 
demonstrated that IL-17RA in K13+ SEL cells is essential for immunity to OPC (31). 
Similar to the IL-17R, the IL-22 receptor is expressed mainly in non-hematopoietic cells and 
is implicated in gastric C. albicans infections (40), yet remarkably little is known about 
IL-22 signaling and function in the oral mucosa.
Here, we show that IL-22 functions non-redundantly with IL-17 to limit fungal infection. 
Although expression kinetics are similar between these cytokines, there were unexpected 
differences in cellular sources, downstream target gene expression and the nature and 
localization of the essential cytokine-responsive cells within the stratified oral epithelium. 
Transcriptomic analysis revealed that IL-22 signaling through STAT3 induces proliferation 
and survival of BEL cells. Moreover, IL-22-dependent signals are required for renewing the 
IL-17-responsive SEL. Hence, IL-22/STAT3 signaling ‘licenses’ the oral IL-17 signaling 
response, despite acting in a distinct epithelial layer.
RESULTS
IL-22 is non-redundant with IL-17 in mediating protection against OPC
To compare the roles of IL-22 and IL-17 in OPC, we tracked the time course of Il22 and 
Il17a mRNA expression in the oral mucosa (tongue) of wild-type (WT) immunocompetent 
mice following sublingual C. albicans infection (41, 42). Il22 and Il17a transcripts were not 
detectable at baseline but were induced contemporaneously at ~16–24 h post-infection (p.i.). 
Expression of both peaked at 48 h and returned to undetectable levels by 96 h (Fig. 1A). As 
previously observed (12), Il22−/− mice were susceptible to OPC, with fungal loads 
consistently averaging ~103 CFU/g of tongue tissue at 4–5 days p.i., whereas control WT 
mice fully cleared the infection by this time point (Fig. 1B). Fungal loads in Il22−/− mice 
were typically ~1/2 log lower than in mice with IL-17 signaling defects (Il17ra−/− or 
Act1−/−), also consistent with prior findings (Fig 1B) (12, 14, 43).
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We next evaluated the impact of IL-22 on antifungal events in OPC. In line with previous 
data, Il17ra−/− mice exhibited impaired neutrophil recruitment to the tongue following 
infection, measured at day 2 (12). Unexpectedly, Il22−/− mice showed increased oral 
neutrophil frequencies and numbers (Fig. 1C, fig. S1A), despite no differences in fungal load 
compared to Il17ra−/− mice at this time point (fig. S1B). Il17a and Il17f mRNA were 
elevated in Il22−/− mice, which may explain this observation (Fig. 1D, E). Because mice are 
naïve to C. albicans, the IL-17 produced during a first encounter derives from innate immune 
cells (43–47). We previously showed that antigen-independent CD4+TCRαβ+ cells that 
express IL-17 [‘natural’ Th17 cells, nTh17 (48)] are required for effective immunity to OPC 
(29, 44, 49). These nTh17 cells undergo proliferative expansion during the first two days of 
C. albicans infection in an IL-1R-dependent manner (28, 29, 44). In Il22−/− mice, the 
frequencies of proliferating (Ki67+) CD4+TCRαβ+ cells were comparable to WT mice 
following infection (fig S1C), indicating that IL-22 does not regulate nTh17 proliferation.
In view of the many similar functions ascribed to IL-22 and IL-17 at mucosal surfaces (50), 
we asked whether IL-22 acts redundantly with IL-17 in OPC. Treatment with neutralizing 
Abs against IL-22 in Act1−/− mice (which are fully impaired for IL-17R signaling (51)) 
resulted in higher fungal burdens than isotype-treated controls (Fig. 1F). Similarly, blocking 
IL-17A in Il22−/− mice led to higher fungal burdens compared to isotype-treated controls 
(Fig. 1G). Weight loss was more pronounced in mice lacking IL-22 than in WT mice, but 
addition of anti-IL-17A Abs did not cause further weight loss (Fig 1H). Thus, IL-22 and 
IL-17 act cooperatively but non-redundantly to control OPC.
Determinants of IL-22 production in acute OPC
Conventional adaptive Th17 responses to C. albicans are triggered by sensing of β-glucans 
in the fungal cell wall via the Dectin-1/CARD9 signaling, which induces Th17-polarizing 
cytokines (IL-23 and IL-6) (52–58). Here, we assessed the essential triggers of IL-22 in 
innate responses to OPC. As expected, Il23r−/− mice showed impaired oral Il22 expression 
following C. albicans infection (Fig 2A), consistent with elevated fungal loads seen in Il23r
−/− mice (12, 30). However, mice lacking Dectin-1 (Clec7a−/−) or CARD9 induced Il22 
mRNA normally (Fig. 2A). In some settings, IL-22 is induced in Th17 cells by the aryl 
hydrocarbon receptor (AhR) or serum amyloid A (SAA) (59, 60). However, Ahr−/− mice did 
not exhibit an obvious deficit in Il22 induction and were resistant to OPC (fig. S2A, B). 
Similarly, SAA1/2-deficient mice were resistant to OPC and Il17a, Il17f and Il22 were 
induced normally in the oral mucosa (fig. S2C, D). Since these prototypical IL-22-inducing 
signals were dispensable for acute IL-22 induction, we next evaluated the role of 
candidalysin, a recently-described trigger of anti-Candida immunity. This fungal cytolytic 
peptide is generated by proteolytic cleavage of the fungal Ece1 protein (encoded by the 
ECE1 gene). Candidalysin is produced only by hyphae and is needed for optimal expression 
of IL-17 and proliferation of nTh17 cells after oral C. albicans challenge (29, 61). WT mice 
were infected with C. albicans strains lacking either the full ECE1 gene (ece1Δ/Δ), or just 
the candidalysin peptide (ClysΔ/Δ), or an ECE1 re-complemented strain (Rev). Infection 
with ece1Δ/Δ or ClysΔ/Δ caused reduced Il22 mRNA expression compared to Rev (Fig 2B). 
IL-22 protein levels were similarly affected, assessed using IL22TdTomato reporter mice 
(62) (fig. S2E). Notably, these strains showed similar fungal burdens at this time point (fig. 
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S2F). Thus, IL-23 and candidalysin but not Dectin-1/CARD9, AhR or SAA1/2 are required 
for innate IL-22 production during OPC.
We next delineated the oral cellular sources of IL-22 during OPC using bone marrow (BM) 
BM chimeras created from WT and Il22−/− mice. As expected, mice receiving Il22−/− BM 
regardless of host genotype developed OPC, indicating that IL-22 in hematopoietic cells was 
required for C. albicans clearance (Fig. 2C). We then analyzed tongue tissue from 
IL22TdTomato reporter mice at day 2 p.i., the time point when Il22 mRNA expression peaks 
(Fig 1A). There were almost no detectable CD45+TdTomato+ cells prior to infection, 
indicating that IL-22 is not expressed in the oral mucosa at baseline. After infection, 
however, a substantial population of reporter-positive cells was present (Fig. 2D). Of these, 
γδ-T cells constituted the dominant TdTomato+ population (58%), followed by 
CD4+TCRαβ+ cells (26%). A population of CD4−TCRαβ+ cells (8%) and of TCR-negative 
cells (8%) also expressed the reporter (Fig 2D). This expression pattern contrasts to some 
extent with that of IL-17, based on prior studies using an IL-17A fate tracking reporter 
mouse (63) (Fig 2E) (29, 44).
IL-22 signaling in the basal epithelial layer is required to control OPC
IL-22 signals via the IL-10R2 and IL-22RA1 subunits, and the latter is shared among several 
cytokines (64). Il22ra1−/− mice showed a similar, albeit not statistically identical, 
susceptibility to OPC compared to Il22−/− mice (Fig. 3A); the difference could be indicative 
of a contribution of other IL-22R-dependent cytokines, though this possibility was not 
pursued. By 14 days p.i., most Il22ra1−/− mice had cleared the infection (fig. S3A), which 
contrasts with Il17ra−/− mice that were previously shown to maintain oral fungal loads as 
long as 17 days p.i. (12, 31). To identify cell compartments requiring IL-22RA1 in OPC, we 
created reciprocal BM chimeras with WT and Il22ra1−/− mice. Regardless of BM source, 
WT recipients were resistant to OPC, whereas irradiated Il22ra1−/− recipients failed to clear 
C. albicans (Fig. 3B). Thus, IL-22RA1-mediated signaling in non-hematopoietic cells is 
required for effective antifungal immunity.
Oral epithelial tissue is characterized by morphologically distinct expression of cytokeratins. 
Keratin 13 (K13) is expressed in differentiating SEL cells in the post-mitotic, terminally 
differentiated layer, which overlies the proliferative K14-expressing BEL (35). 
Consequently, K13+ epithelial cells make first contact with C. albicans during hyphal 
invasion and are highly subject to fungal-induced tissue damage. Moreover, this SEL layer is 
then sloughed and swallowed as part of the antimicrobial clearance response (34). The SEL 
is replenished by proliferation of the underlying basal K14+ cells which have stem-like 
properties, but how this is controlled in OPC is unclear. Immunofluorescent (IF) staining 
indicated that IL-22RA1 was prominent in the K14+ BEL, with some staining in K13+ SEL 
and papillae (Fig 3C). Isotype controls verified Ab specificity (fig. S3B, C).
To define the relative contributions of IL-22RA1 in oral epithelial cell subtypes, Il22ra1fl/fl 
mice were crossed to K13Cre or K14CreERT2 mice (31, 65). Conditional deletion of Il22ra1 in 
SEL and BEL was efficient, as verified by IF (Fig 3D, E). Il22ra1K13 mice were resistant to 
OPC (mean fungal load ~19), indicating that IL-22 signaling in SEL is dispensable for 
fungal control (Fig 3D). Remarkably, these results show that IL-22 signals in a spatially 
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distinct manner from IL-17, since deletion of Il17ra in K13+ cells resulted in significant 
susceptibility to OPC (31). To delete IL-22RA1 in BEL, Il22ra1K14ERT2 mice and controls 
(Il22ra1fl/fl, Il22ra1fl/-K14ERT2, Il22ra1K14ERT2) were administered tamoxifen for 5 days and 
infected with C. albicans. In contrast to Il22ra1K13 mice, loss of Il22ra1 in K14+ cells led to 
markedly increased susceptibility to OPC (fungal load ~508), demonstrating that IL-22R 
signaling is commensurate with its expression profile in the BEL (Fig. 3E). Hepatic IL-22R 
is needed for pulmonary bacterial immunity (66), but mice with a liver-specific deletion of 
IL-22RA1 (Il22ra1Alb) were resistant to OPC (fig. S3D). Hence, these data show that 
IL-22RA1 signaling in the K14+BEL, but not the K13+SEL, is required for oral fungal 
control, and accordingly that IL-17 and IL-22 function in different epithelial compartments.
IL-22 activates STAT3 in the BEL to sustain epithelial proliferation and antifungal immunity
To determine the mechanisms by which IL-22 promotes immunity during OPC and whether 
this differs from IL-17-driven responses, we evaluated RNASeq profiles of total tongue 
mRNA from C. albicans-infected Il22−/−, II17ra−/− and WT mice. In keeping with the 
observation that IL-17 and IL-22 act non-redundantly, there were distinct gene sets induced 
by IL-22 (368 genes) versus IL-17RA (931 genes). There were also many overlapping genes 
controlled by both cytokines (215 genes) (Fig. 4A). As expected (15), Geneset Enrichment 
Analysis (GSEA) identified downregulation of IL-6/STAT3 gene sets in Il22−/− mice 
compared to Il17ra−/− and WT mice, with a normalized enrichment score (NES) of 1.4 
(P<0.05) (Fig. 4B). Consistently, Ingenuity Pathway analysis identified STAT3 as a central 
upstream regulator that integrates the IL-22 and IL-17RA transcriptional networks (Fig. 4C). 
Within this network, STAT3 was connected to proliferation and apoptosis genes and to 
transcription factors that regulate inflammation such as NF-κB/IκBξ (Nfkbiz) and MAPK/
AP-1 (Fig. 4C). In line with these bioinformatic predictions, IL-22 induced STAT3 
phosphorylation and IκBξ expression in a human oral epithelial cell line (fig. S4A, B).
In vivo, STAT3 phosphorylation was evident in the BEL after C. albicans infection, but 
markedly reduced in Il22−/− and Il22ra1−/− mice (Fig. 4D, F). Unexpectedly, STAT3 
phosphorylation was increased in Il17ra−/− BEL during OPC, possibly due to elevated Il22 
expression in these mice (Fig 4D, E). These results show that, even though numerous stimuli 
have potential to activate STAT3, the dominant STAT3 response during OPC is mediated by 
IL-22RA1-dependent cytokines. This finding also supports the idea that there may be 
defective IL-22-driven signaling in the pathogenesis of OPC associated with STAT3 
mutations (e.g., Job’s syndrome). K14 staining intensity by IF was reduced in Il22ra1−/− 
mice compared to WT (Fig 4F). This was commensurate with RNASeq data that showed 
reduced Krt14 mRNA in Il22−/− mice (Fig. 4A, data not shown), a phenomenon also 
observed in skin (67). Additionally, we confirmed that mice lacking STAT3 in K14+ but not 
K13+ cells were susceptible to OPC (Fig 4G, H, fig. S4C). Together, these data demonstrate 
a central role of STAT3 in the oral epithelium that sustains antifungal immunity.
GSEA also revealed increased expression of mitotic spindle checkpoint genes and decreased 
expression of cell death-associated genes in WT versus Il22−/− mice (Fig. 5A), NES 1.4 
(P<0.01) and 1.5 (P<0.003), respectively. Specifically, positive cell cycle regulatory genes 
(Stat3, Jun, Sphk1) were reduced and negative regulators of cell cycle (Cdkn1c, Ddit3, Ets1) 
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were elevated (Fig 5B). Concordantly, Il22ra1−/− mice showed decreased IF staining of Ki67 
in K14+ cells following C. albicans infection, indicating that IL-22 is a major driver of BEL 
proliferation (Fig. 5C). Consistently, there was a trend to decreased bromodeoxyuridine 
(BrdU) incorporation in Il22−/− K14+ BEL cells following oral C. albicans infection (fig. 
S5A). We next evaluated cell cycle progression in EpCAM+ epithelial cells from Il22−/− and 
WT tongues by BrdU and 7-aminoactinomycin D (7-AAD) staining. As shown, there were 
comparable proportions of cells in the Gap2/mitotic (G2/M) phase, fewer in the synthesis (S) 
phase and more in the G0/G1 phase (Fig. 5D, fig. S5A, B). GSEA also suggested enrichment 
of cell death-associated and DNA damage response genes (Fig 5A, fig. S5C). Indeed, Il22−/− 
mice had higher frequencies of active caspase 3+ and TUNEL+ epithelial (EpCAM+) cells 
following infection (Fig. 5E, F, G). Hence, IL-22 promotes BEL proliferation during OPC, 
while limiting accumulation of apoptotic cells.
IL-22 restores IL-17R expression and signaling in SEL to sustain antifungal immunity in 
OPC
In stratified epithelia such as the oral mucosa, proliferating BEL regenerate the post-mitotic 
SEL (35, 36). Consistently, genes implicated in tissue repair, keratinization and epithelial 
differentiation were impaired in Il22−/− mice compared to WT (Fig. 6A). Though IL-17RA 
signaling in K13+ SEL cells is critical for immunity to OPC (31), the factors that restore the 
SEL after sloughing have not been well defined. In view of the impaired proliferation of 
BEL in Il22−/− mice, we hypothesized that IL-22 might indirectly impact IL-17 signaling in 
OPC by restoring the IL-17RA-expressing SEL. Indeed, transcriptomic data and qPCR 
revealed that there was decreased Il17ra mRNA expression in Il22−/− tongue (Fig. 6B, C). IF 
staining revealed loss of IL-17RA in the SEL of WT mice after C. albicans infection, which 
was even more pronounced in Il22−/− mice (Fig. 6D). Flow cytometry also demonstrated that 
IL-17RA cell surface expression was reduced in WT and Il22−/− CD45−EpCAM+ oral 
epithelial cells following C. albicans infection, though the difference between WT and 
Il22−/− mice was modest (Fig. 6E). Consistent with reduced IL-17RA in oral epithelium, 
canonical IL-17 target genes associated with immunity to C. albicans were downregulated in 
Il22−/− mice during OPC, including the essential antimicrobial peptide β-defensin-3 (Defb3) 
(Fig 6F). Collectively, these data support a model in which IL-22 signaling promotes BEL-
intrinsic signals that mediate anti-Candida immunity. Accordingly, IL-22 ‘licenses’ IL-17R 
signaling by renewing the SEL and thereby restoring the capacity of the tissue to respond to 
IL-17R, which is vital in controlling OPC (Fig 6G).
DISCUSSION
Although IL-22 and IL-17 are both produced by Type 17 cells, these cytokines are distinct in 
structure, receptors, and downstream signaling pathways (50). Even so, they are usually 
viewed interchangeably in the context of mucosal immunity. The protective function of 
IL-22 in oral candidiasis has been recognized for some time, yet its mechanisms of action 
are incompletely understood. In non-oral manifestations of C. albicans infection or 
colonization (systemic, vaginal, dermal or gastric), IL-22 is not necessarily protective, 
emphasizing that specific cytokine responses even to the same pathogen are influenced by 
tissue milieu (12, 40, 68–71).
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While multiple families of CMC patients have been identified with mutations in IL-17R 
pathway genes (7, 72, 73), thus far no humans with genetic IL-22-deficiencies have been 
reported. Nonetheless, it does not necessarily follow that this cytokine is unimportant in 
humans, only that its contribution to host defense is likely to be more modest than that of 
IL-17, or possibly that IL-22 deficiency is not compatible with life for some other reason. 
The former would be analogous to the role of IL-17F. In mice, loss of IL-17F alone does not 
cause OPC, yet dual blockade of IL-17F and IL-17A significantly increases susceptibility 
(43, 51). In humans, a family with IL-17F mutations has been described with CMC, 
suggesting a role in mucosal candidiasis (73). AIRE-deficient humans have circulating 
neutralizing Abs against IL-17F, IL-22 and IL-17A, thought to help explain the CMC 
manifestations in these patients (9, 16–18). In most mammals, though not mice, Th17 cells 
also express IL-26, a member of the same cytokine family as IL-22, and this cytokine may 
be also a target of biologic therapy (74); however, there is no evidence for autoantibodies 
against IL-26 in AIRE deficiency nor have IL-26-deficient humans been described (16).
The mechanisms by which IL-17 and IL-22 act in OPC are divergent (50). Whereas loss of 
IL-17 impairs neutrophil recruitment (12, 31), IL-22 deficiency led to increased neutrophil 
tissue infiltration, presumably because Il17a is concomitantly elevated. These opposing 
activities on the neutrophil response may help to restrain excessive inflammation. 
Interestingly, the capacity of IL-17 to drive oral neutrophil recruitment in OPC is not 
observed by all who use this OPC model (28, 75), possibly reflecting altered microbiota or 
other distinctions among animal facilities. Hence, the events controlling oral mucosal 
immunity are complex and dynamic.
The immunology of the oral cavity is less well understood than other mucosae (34, 37). In 
part, this is due to technical challenges associated with isolating cells from oral mucosal 
sites and the paucity of tools available to interrogate cell types within this tissue (76). We 
show here that IL-22 and IL-17 are produced by and function in distinct oral cell subtypes in 
the setting of OPC. Unlike humans, mice do not harbor C. albicans as a commensal 
organism, and hence acute oral infection with C. albicans reflects an innate, not adaptive, 
immune response. In prior studies, IL-17 was shown to be produced by several innate 
lymphocyte subsets, including TCRαβ+ ‘natural’ Th17 cells (nTh17), which express CD4, 
have a diverse TCR repertoire, and are activated in a non-antigen-specific manner (29, 44). 
IL-17 is also detected to a lesser extent in γδ-T cells and, in some reports, ILC3 cells (29, 
43, 44). Upon a recall encounter to C. albicans, mice generate conventional, antigen-specific 
Th17 cells that additionally contribute to the IL-17-producing pool, where they augment 
immunity to C. albicans (46, 47, 77). C. albicans-specific Th17 cells are abundant in 
humans, as C. albicans is encountered very early in life. Moreover, C. albicans-specific Th17 
cells recognize and provide cross-reactive protection against other fungal species, which is 
likely why maintaining C. albicans as a commensal is evolutionarily advantageous (78–81).
We observed that γδ-T cells were the predominant oral source of IL-22 during OPC, 
followed by nTh17 cells and TCR-negative cell types. These results parallel observations 
made in skin upon C. albicans infection, where γδ-T cells are the major source of Type 17 
cytokines (52). Since the sources of these cytokines were identified using reporter mice 
which may under-report, defining the relative differences in sources of IL-17 and IL-22 is 
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worth pursuing in more detail (62, 63). Nonetheless, the induction requirements for IL-22 
during OPC are remarkably similar to that of IL-17; namely, IL-23 and the fungal peptide 
candidalysin are crucial, whereas classical fungal PRRs such as Dectin-1, CARD9 or 
activators of conventional Th17 cells such as AhR or SAA1/2 are dispensable (29, 59, 60, 
77). The finding that AhR was not essential to induce IL-22 or clear C. albicans from the 
mouth, although initially unexpected, is consistent with observations that AhR facilitates 
EGFR phosphorylation in OPC, a key step in fungal adhesion, endocytosis and invasion in 
OECs (25, 27, 82, 83).
IL-17 and IL-22 are typically depicted signaling on the same cell types to mediate mucosal 
immunity, which is the case in non-stratified epithelia such as gut or lung (50, 84). Hence, 
we did not anticipate that IL-17 and IL-22 would act upon spatially distinct cell types in the 
oral mucosa. To show this, we made use of a mouse that expresses Cre under control of the 
murine Krt13 proximal promoter, one of the first tools allowing relatively specific deletion 
in the oral mucosa (31). The K13Cre mouse deletes conditionally in the SEL of the tongue, 
buccal mucosa, esophagus and vaginal tract, with no detectable Cre activity in BEL of any 
tissue examined. Using this system, we found that IL-17RA acts predominantly within K13+ 
cells in the setting of OPC, with fungal burdens only slightly reduced compared to a full 
Il17ra−/− animal (31). In contrast, deletion of IL-22RA1 or STAT3 in K13+ SEL did not 
impact fungal clearance during OPC. GSEA of RNASeq data predicted a role for the 
IL-22RA1/STAT3 axis in tissue proliferation and repair during C. albicans infection. Indeed, 
IL-22R signaling, presumably through STAT3, was vital for proliferation and survival of the 
K14+BEL, consequently replenishing the SEL. Thus, IL-22 indirectly permits essential 
IL-17-driven antifungal events to occur by restoring the post-mitotic superficial layer where 
IL-17RA is expressed. This spatial stratification of the IL-22R versus the IL-17R enforces 
the specificity, diversification, and integration of cues that ensure oral epithelial integrity, 
restrain undue inflammation and promote antifungal immunity.
The oral mucosa is among the most resilient epithelial surfaces (85). By virtue of their 
location, superficial K13+ OECs are the first to make contact with C. albicans. In its non-
invasive yeast (commensal) form, C. albicans causes no damage to the SEL, which was 
recently shown to be due the fact that this form of the fungus does not produce the pore-
forming virulence factor candidalysin (61). Accordingly, there is insufficient expression of 
IL-1 or other DAMPs that would activate innate lymphocytes to produce IL-17 or IL-22. 
This creates an environment where benign commensal C. albicans colonization is favored. 
However, in conditions that are conducive to hypha formation and invasion into tissue, a 
different scenario ensues. As part of the response to fungal invasion, the damaged SEL is 
sloughed and swallowed, which helps to clear C. albicans. The resulting epithelial cell 
damage also triggers production of IL-1 and IL-36, which promote IL-17 and IL-23 
expression, respectively (28–30, 86). IL-17R signaling in the SEL upregulates chemokines 
that recruit neutrophils as well as β-defensins that exert direct antifungal activity (12, 31, 33, 
87). Hyphal invasion thus establishes an inflammatory milieu that is initiated by 
candidalysin-induced SEL damage, potentiated by IL-17- and candidalysin-induced 
effectors such as IL-1 and IL-36, and ultimately resolved upon clearance of the pathogen 
(29, 88).
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IL-22 acts in many epithelial surfaces. Events in the oral epithelia are reminiscent of skin, 
where K14+ stem cells resupply superficial epithelial cells to maintain barrier integrity (36, 
89). The skin also possesses ‘memory’ properties that accelerate tissue repair after future 
insults, though whether this occurs in the mouth is unknown (90). IL-22RA1+ epithelial cells 
in colonic epithelium maintain genome integrity and limit apoptotic cell accumulation 
during genotoxic stress (91). Similarly, IL-22 signaling in the BEL during OPC promotes 
replacement of damaged epithelial cells, prevents accumulation of inflammatory apoptotic 
cells, preserves genome integrity and, as shown here, helps maintain IL-17-driven antifungal 
activities.
IL-22 maintains the intestinal epithelial barrier during intestinal colonization of C. albicans 
(40, 92). Unlike the mouth, IL-17 is not protective in gut but rather promotes a tissue-
destructive inflammatory cycle in response to C. albicans colonization (93). In fact, IL-17 
signaling in gut is generally more reparative than inflammatory (94–98), which is thought to 
explain why anti-IL-17 biologic therapies failed in treatment trials of Crohn’s disease (99). 
Anti-IL-17 biologics are associated with low but statistically significant rates of OPC, 
though it is rare for patients to stop therapy for this reason (100). Anti-IL-22 antibodies are 
under evaluation for skin pathologies such as atopic dermatitis (101), but rates of C. albicans 
infections have not been reported. Our data predict that combinations of anti-IL-17 and anti-
IL-22 could result in more severe mucosal candidiasis infections than either therapy alone.
GSEA data show that STAT3 is an integrating hub between the IL-22 and IL-17 signaling 
networks. The pathways inferred from bioinformatics data (proliferation, cell cycle analysis, 
and apoptosis) are commensurate with the known roles of IL-22 and STAT3 in epithelial 
proliferation and repair (64). Surprisingly, IL-22/STAT3 genesets and phosphorylation of 
STAT3 were enriched in the Il17ra−/− mice, even though expression of other STAT3-
activating cytokines (e.g., IL-6 and G-CSF) were impaired in the absence of IL-17 signaling. 
This could be due to elevated Il22 expression in Il17ra−/− mice, but likely reflects overall 
perturbation of immune response networks inferred from GSEA that may involve STAT3. 
Susceptibility to CMC in Job’s syndrome patients with STAT3 mutations is attributed to 
impaired STAT3-dependent Th17 differentiation (9). However, in acute OPC in mice, STAT3 
in CD4+ T cells is not required to control fungal loads (44). Thus, STAT3 likely modulates 
antifungal immunity beyond the hematopoietic compartment. Supporting this, we found that 
HIES patients exhibit impairments in salivary antifungal immunity, with reduced levels of 
salivary AMPs including β-defensins and histatins (102). STAT3 deficiency in lacrimal 
epithelial cells enhances apoptosis, causing a Sjögren’s syndrome-like phenotype (103). 
STAT3 also regulates metabolism in various settings to meet energy needs for cell 
proliferation, and STAT3-regulated functions in mitochondria are becoming increasingly 
appreciated (104–106). Hence, the IL-22/STAT3 axis coordinates antimicrobial immunity in 
a variety of environments.
In summary, these results reveal a deeper understanding of the antimicrobial defense 
functions of oral epithelial cells and a complex interplay between distinct cytokines of the 
Type 17 axis. It is clear that cells within the oral epithelium are not simply physical barriers, 
but are topographically structured sentinels that work in concert to dictate the outcome of 
oral C. albicans colonization, the most common fungal infection of humans (4, 107).
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The objective of this study was to delineate functions of IL-22 in immunity to OPC. We used 
a mouse model of C. albicans infection combined with knockout mouse and fungal strains to 
interrogate sources and activators of IL-22, genes induced in the oral mucosa, and cell-
specific functions of this cytokine in vivo. Sample sizes were determined by power analyses 
from pilot or previously published data. Mice of both sexes were assigned randomly to 
experimental cohorts. Unless noted, experiments were done 2–3 independent times. Data 
from multiple experiments were pooled unless noted. Investigators were not blinded to 
groups. No data were excluded. Endpoints were selected based on prior kinetic studies (1–2 
days for gene expression or IF staining in OPC, 4–5 days for fungal load enumeration).
Mice
IL-22TdTomato, Il22ra1fl/fl, K13Cre, Card9−/−, K14CreERT2, STAT3fl/fl, Saa1/2, and Il23r−/− 
mice were described (31, 62, 66, 108, 109). Il17ra−/− mice were from Amgen and Il22−/− 
mice were from Genentech. All mice are available by MTA. Other mice were from JAX or 
Taconic Farms. Mice were on the C57BL/6 background and housed in SPF conditions. 
Experiments were performed on age-matched mice (6–10 weeks) of both sexes. BM 
chimeras were generated by irradiation (900 rads) followed by i.v. injection of 106 femoral/
tibial BM. Immune reconstitution after 6–9 weeks was verified by CD45.1/2 FACS staining. 
Experiments were performed in accordance with protocols approved by the University of 
Pittsburgh IACUC and NIAID and followed guidelines in the Guide for the Care and Use of 
Laboratory Animals of the NIH.
Oropharyngeal candidiasis (OPC) and fungal strains
OPC was induced by sublingual inoculation with C. albicans (strain CAF2–1 or SC5314)-
saturated cotton balls for 75 min under anesthesia, as described (12, 41). Tongue 
homogenates were prepared on a GentleMACS homogenizer (Miltenyi Biotec) with C-tubes, 
and CFU was determined by serial dilution plating on YPD/Amp agar. Anti-IL-22 Abs 
(Genentech, clone 8E-11) or control IgG1 (Bio X Cell) (150 μg) were injected i.p. on days 
−1, 0, 1, 2, 3 relative to infection. Anti-IL-17A or IgG2a control Abs (200 μg) were from 
Janssen Research & Development LLC (110) and administered i.p. on days −1, 1, and 3. 
Mutant C. albicans lacking the full Ece1 protein(ece1Δ/Δ), the candidalysin peptide 
(ece1Δ/Δ+ECE1Δ184–279, herein called ClysΔ/Δ) or a complemented strain (ece1Δ/Δ+ECE1, 
herein called Rev) were described (61).
Flow cytometry
Flow cytometry of tongue homogenates was performed as described (44). Tongues were 
digested with DNaseI (1 mg/ml, Roche), and collagenase IV (0.7 mg/ml) in HBSS at 37°C. 
Filtered cell suspensions were stained directly or separated by Percoll gradient 
centrifugation. Abs were from eBioscience, BD Biosciences, BioLegend or Abcam. 
Proliferation was assessed using the Foxp3/Transcription factor Buffer kit (eBioscience) 
with Ki67-APC/PerCP (Cell Signaling #9129). To assess apoptosis, CD45−EpCAM+ cells 
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were stained with caspase-3 apoptosis kit (BD Biosciences). For cell cycle analysis, mice 
were injected i.p. with 1 mg bromodeoxyuridine (Abcam, BrdU flow kit, BD Biosciences, # 
552598) on day 1 p.i. and tongues harvested 24 h later. Data were acquired on an LSR 
Fortessa and analyzed with FlowJo (BD Biosciences).
qPCR, RNASeq and GSEA
Total tongue RNA was extracted using RNeasy kits (Qiagen) after homogenization in a 
Gentle MACS Dissociator (Miltenyi Biotec). RNA from TR146 cells was extracted in RLT 
buffer. Real time PCR (qPCR) was performed as described and normalized to Gapdh (29). 
Primers were from QuantiTect Primer Assays (Qiagen). For RNASeq, cDNA libraries were 
prepared from tongue RNA harvested day 1 p.i. (Nextera XT Kit) and RNASeq was 
performed on the Illumina NextSeq 500 platform by the Health Sciences Sequencing Core at 
the University of Pittsburgh. Sequencing reads were annotated and aligned to the UCSC 
mouse reference genome (mm10, GRCm38.75) using HISAT (111). HISAT alignment files 
were used to generate read counts for each gene, and determination of differential gene 
expression was performed using the DE-seq package from Bioconductor (112). Unbiased 
hierarchical clustering of differentially expressed genes with P<0.05 was calculated using 
CLC Genomics Workbench and Partek software. Relative expression values in heat maps are 
TPM (transcripts per kilobase million) values per sample that have been divided by the 
average expression across all samples. Partekflow and GSEA from the Broad Institute were 
used to calculate enrichment of genes in each set. Additional bioinformatics assistance was 
from the University of Pittsburgh Center for Research Computing and Health Sciences 
Library.
Histology, immunofluorescence and immunocytochemistry
Cryosections were stained per the Cell Signaling immunofluorescence protocol (https://
www.cellsignal.com/contents/resources-protocols/immunofluorescence-general-protocol/if). 
Abs: IL-22RA1 (R&D Systems, clone MAB42941), Keratin 13 and Keratin 14 (Abcam, 
EPR3671 and EPR17350; Invitrogen LL002), Ki67 and anti-p-STAT3 (Tyr705) (Cell 
Signaling, #9145), IL-17RA (Amgen, clone M751). TUNEL staining was performed with an 
Apoptosis Detection kit (Millipore). Images were acquired on an EVOS FL microscope 
(Life Technologies). TUNEL+ cells were enumerated from 10 random fields per slide.
Cell culture, cytokine stimulations and immunoblotting
TR146 cells were cultured in DMEM-F12 with 15% FBS and antibiotics as described (31). 
For immunoblotting, 3–5 × 105 cells were seeded in serum-free DMEM-F12 overnight prior 
to cytokine stimulation. Recombinant human IL-22 (Peprotech) was used at 100 ng/ml. Abs 
to STAT3 were from Cell Signaling (#12640) and Abs to actin were from Millipore (clone 
C4-EMD).
Statistics
Data were analyzed on Prism (GraphPad). PCR data was analyzed by one-way ANOVA, 
Student’s t-test and post-hoc tests were used as indicated in figure legends. Fungal load data 
are presented as geometric mean ± SD and analyzed by ANOVA and Mann-Whitney U test. 
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Each symbol represents one mouse unless indicated. *P<0.05, **<0.01, ***<0.001, 
****<0.0001.
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Abbreviations:
AhR aryl hydrocarbon receptor
AMP antimicrobial peptide
BD β-defensin
BEL basal epithelial layer
BM bone marrow
BrdU bromodeoxyuridine
CFU colony forming units
Clys candidalysin
CMC chronic mucocutaneous candidiasis
GSEA gene set enrichment analysis
HIES hyper-IgE syndrome (Job’s)
OEC oral epithelial cell
nTh17 natural Th17
NES normalized enrichment score
OPC oropharyngeal candidiasis
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SAA serum amyloid A
SEL superficial epithelial layer
TUNEL terminal deoxynucleotidyl transferase nick-end labeling
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Figure 1. IL-22 protects against OPC non-redundantly with IL-17RA
The indicated mice were sublingually inoculated with cotton ball-saturated PBS (Sham) or 
C. albicans (OPC). Each symbol represents one mouse. A. Total mRNA from tongue 
homogenates of infected WT mice was subjected to qPCR for Il22 and Il17a and normalized 
to Gapdh at each time point. Graphs show mean ± SEM. Data are pooled from 4–9 mice per 
group. B. Fungal burdens were determined by CFU enumeration on YPD/Amp agar at day 5 
p.i. Graphs show geometric mean ± SD. Data were pooled from 3 independent experiments. 
Dashed line indicates limit of detection (~30 CFU/g). C. Tongue homogenates were 
prepared on day 2 p.i. Left: A representative FACS plot showing percent of CD11b+Ly6G+ 
neutrophils (gated on live, CD45+ cells). Right: Data from 3 independent experiments. D-E. 
Il17a and Il17f in total RNA from tongue on day 2 p.i. was assessed by qPCR relative to 
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Gapdh. Graphs show mean ± SEM relative to Sham-infected WT mice. F. Mice were 
injected i.p. with anti-IL-22 or isotype control IgG (150 μg) on days −1, 0, 1, 2, and 3 
relative to infection. CFU was assessed on day 4, pooled from 2 independent experiments. 
G. Mice were treated with anti-IL-17A or isotype control (IgG2a) (200 μg) injected i.p. on 
days −1, 1, and 3 relative to infection. CFU was assessed on day 5, pooled from 3 
independent experiments. H. Weight loss was assessed daily, shown relative to day 0 in mice 
from panel F. Data were analyzed by ANOVA or Student’s t-test, with Mann-Whitney U test 
for fungal load analysis.
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Figure 2. Determinants of IL-22 induction in acute OPC
The indicated mice were subjected to OPC. Each symbol represents one mouse A. Tongues 
were harvested on day 2 p.i. and Il22 mRNA was assessed by qPCR, normalized to Gapdh. 
Graphs show mean ± SEM relative to sham-infected WT mice. B. WT mice were infected 
with the indicated C. albicans strains. Il22 mRNA in tongue on day 2 p.i. was assessed by 
qPCR, normalized to Gapdh. Data were pooled from 2 independent experiments. C. BM 
from indicated donors was transferred into irradiated recipients. After 6–9 weeks, mice were 
subjected to OPC and fungal burdens assessed on day 5 p.i. Data were pooled from 2 
experiments. D. On day 2 p.i., tongue homogenates from IL22TdTomato mice were stained 
for the TCRβ and TCRγδ and gated on the live CD45+TdTomato+ population. Left: 
representative FACS plots. Right: Pooled results from 3 independent experiments. Each 
symbol represents data from 2 pooled tongues. Data were analyzed by ANOVA or Student’s 
t-test, with Mann-Whitney U test for fungal load analysis. E. Comparisons of the relative 
percentages of IL-22+ cells (left) or IL-17+ cells (data from (29)) isolated from tongues of 
mice 2 days p.i. and analyzed by flow cytometry.
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Figure 3. IL-22 signaling in the oral basal epithelial layer is required for protection against OPC
The indicated mice were subjected to OPC. A. Fungal burdens were assessed on day 5 p.i. 
Bars show geometric mean ± SD. Data were pooled from 2 independent experiments. B. BM 
from indicated donors was transferred into irradiated recipients. After 6–9 weeks, mice were 
subjected to OPC and fungal burdens assessed on day 5 p.i. Data were pooled from 2 
experiments. C. Frozen sections from WT tongues were co-stained with DAPI and Abs 
against K13, K14 or IL-22RA1. Suprabasal and basal epithelial layers are indicated. Images 
are representative of a minimum of 3 sections. Size bar = 200 μm. D. Top: Fungal burdens 
were assessed on day 5 p.i. Data are pooled from 3 independent experiments. Bottom: IF 
staining of tongues from the indicated mice were co-stained with DAPI and α-IL-22RA1 
Abs. Size bar = 200 μm. E. Top: All mice except Il22−/− were administered tamoxifen for 5 
days prior to OPC, and fungal burden assessed on day 5 p.i. Bars show geometric mean ± 
SD. Bottom: Frozen sections from tongues from the indicated mice were co-stained with 
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DAPI and α-IL-22RA1. Size bar = 200 μm. Data were pooled from 3 independent 
experiments and analyzed by ANOVA with Mann-Whitney U test.
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Figure 4. STAT3 in oral epithelial cells is required for protection against OPC
A. RNASeq was performed on whole tongue mRNA from WT, Il22−/− and Il17ra−/− mice 
subjected to OPC and harvested on day 1 p.i. Venn diagram of differentially regulated or 
overlapping genes in infected Il22−/− and Il17ra−/− compared to WT mice. 215 genes were 
regulated both by IL-22 and IL-17RA, whereas 368 genes are regulated only by IL-22, and 
931 genes were regulated only by IL-17RA. B. GSEA enrichment of predicted IL-6/STAT3 
gene sets in Il17ra−/− and Il22−/− mice from panel A. C. Ingenuity Pathway Analysis of 
RNASeq data from panel A, indicating that STAT3 is an upstream regulator integrating Il22- 
and Il17ra- driven transcriptional networks. D. IF staining of tongue frozen sections with 
DAPI and anti-pSTAT3 (Tyr705) in WT, Il22−/− and Il17ra−/− mice harvested 2 days p.i. Size 
bar = 200 μm. E. qPCR of Il22 in tongue mRNA from WT or Il17ra−/− mice at 2 days p.i. 
normalized to Gapdh F. IF staining of DAPI, pSTAT3 (Tyr705) and K14 in WT or Il22ra1−/− 
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mice at 2 days p.i. Size bar = 200 μm. G. The indicated mice were subjected to OPC and 
fungal burden quantified at day 5 p.i.. Data are pooled from 3 experiments H. All mice 
except Il22−/− were administered tamoxifen for 5 d, subjected to OPC and fungal burden 
assessed on day 5 p.i. Bars show geometric mean ± SD. Data was pooled from 3 
experiments. Data analyzed by ANOVA with Mann-Whitney U test.
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Figure 5. IL-22 promotes cell survival and proliferation during OPC
RNASeq was performed on tongue mRNA from WT, Il22−/− or Il17ra−/− mice, isolated 24 h 
p.i. A. GSEA of mitotic spindle checkpoint pathway and cell death pathway genes. 
Normalized enrichment score is shown on Y-axis. B. Heatmap of cell cycle pathway genes 
in global differential gene expression analysis (Partekflow) in WT or Il22−/− mice. C. IF 
staining of DAPI, Ki67 and K14 in WT and Il22ra1−/− mice at 2 days p.i. Data are 
representative of images from 2 mice per group. Size bar = 100 μm. D. BrdU was 
administered 24 h p.i., and tongues harvested on day 2 p.i. Cell cycle/apoptotic status of 
CD45−EpCAM+ cells was determined by bromodeoxyuridine (BrdU) and 7-
aminoactinomycin (7AAD) staining. Data show mean ± SEM. E. Frequency of 
CD45−EpCAM+ cells staining positive for active (cleaved) caspase-3 in tongue homogenates 
at day 2 pi measured by flow cytometry. Left: Representative FACS plot. Right: Pooled data 
from 4 independent samples showing mean fluorescence intensity (MFI) of cleaved Caspase 
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3 within the CD45−EpCAM+ compartment. Data analyzed by Student’s t-test. F. DAPI and 
TUNEL staining of tongue sections from the indicated mice at day 2 p.i. Images are 
representative of 4 mice per group. Size bar = 200 μm. G. Quantification of TUNEL+ cells 
from panel. F. Data analyzed by ANOVA and post-hoc Tukey’s test.
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Figure 6. IL-22 licenses IL-17 signaling during OPC
A. Heatmap of genes implicated in tissue repair, wound healing, keratinization and epithelial 
differentiation. B. Heatmap of IL-17 signature genes in OPC. C. qPCR of Il17ra expression 
normalized to Gapdh in tongue tissue from the indicated mice subjected to OPC and 
analyzed on day 2 p.i.. Data show mean ± SEM relative to sham-infected mice. Data 
analyzed by ANOVA or Student’s t-test. D. IF staining of IL-17RA and DAPI in the 
indicated mice on day 2 p.i. E. IL-17RA expression in CD45−EpCAM+ oral epithelial cells 
in WT or Il22−/− mice during OPC. Top: representative FACS histogram. Bottom: Pooled 
data from 2 independent experiments. Size bar = 200 μm. F. Expression of BD3 (Defb3) 
mRNA in tongue from WT or Il22−/− mice during OPC, normalized to Gapdh. Data 
analyzed by ANOVA or student’s t-test. G. Diagram of stratified oral epithelium during a 
first encounter with C. albicans. Fungal hyphae induces cellular damage and secrete the 
peptide candidalysin, which facilitates tissue invasion and activates innate IL-17- and IL-22-
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producing lymphocytes (see Refs (29, 61)). IL-17 was shown previously to act dominantly 
on K13+ cells of the suprabasal epithelial layer (SEL) (31). In contrast, IL-22/STAT3 
promotes proliferation of the K14+ basal epithelial layer (BEL) that serves to restore the 
IL-17R-expressing SEL, thus maintaining IL-17-induced antifungal signals such as β-
defensins and neutrophil responses that are required to mediate clearance of C. albicans. 
Diagram created on Biorender.com.
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